COVID-19 and gynecological cancer: a review of the published guidelines

Uwins, Christina; Bhandoria, Geetu; Shylasree, TS; Butler‐Manuel, Simon; Ellis, Patricia; Chatterjee, Jayanta; Tailor, Anil; Stewart, Alexandra J.; Michael, Agnieszka

doi:10.1136/ijgc-2020-001634

Cited by 47 publications

(77 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This issue had been discussed, not just from our own experiences. Guidelines and recommendations have been issued by various organizations, including countries with more widespread conditions, such as China, Italy, and the United States [22,23]. According to these guidelines, CCRT for cervical cancer was recommended with high priority, and many patients could receive standard treatment.…”

Section: Susceptibility Of the Treatment Strategies For Ovarian Tumormentioning

confidence: 99%

“…Thus, a strategy of neoadjuvant chemotherapy to interval debulking surgery would be recommended, but this, of course, needs to be balanced with individual patient prognosis, which is a difficult decision [24,25]. Surgery for endometrial cancer was also considered a low priority for early-stage cancer [23]. Ovarian cancer is the most susceptible among the three major gynecological cancers, considering the prognoses and the rate of advanced cancer [26].…”

Section: Susceptibility Of the Treatment Strategies For Ovarian Tumormentioning

confidence: 99%

See 1 more Smart Citation

Impact of the COVID-19 epidemic at a high-volume facility in gynecological oncology in Tokyo, Japan: a single-center experience

et al. 2020

View full text Add to dashboard Cite

Background The number of cases of novel coronavirus disease 2019 (COVID-19) in Japan have risen since the first case was reported on January 24, 2020, and 6225 infections have been reported as of June 30, 2020. On April 8, 2020, our hospital began screening patients via pre-admission reverse transcriptase-polymerase chain reaction (RT-PCR) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and chest computed tomography (CT). Although no patients exhibited apparent pneumonia, treatment delay or changes in treatment plans were required for a few patients based on the results of screening tests. During an emerging infectious disease pandemic, the likelihood of being infected, as well as the disease itself, affects clinical decision making in several ways. We summarized and presented our experience. Case presentation After the introduction of pre-admission screening, RT-PCR and CT were performed in 200 and 76 patients, respectively, as of June 30, 2020. The treatment of five patients, including two patients with cervical cancer, two patients with ovarian tumors, and one patient with ovarian cancer, was affected by the results. Two asymptomatic RT-PCR-positive patients did not develop COVID-19, but their treatment was delayed until the confirmation of negative results. The other three patients were RT-PCR-negative, but abnormal CT findings suggested the possibility of COVID-19, which delayed treatment. The patients receiving first-line preoperative chemotherapy for ovarian cancer had clinically evident exacerbations because of the treatment delay. Conclusion During the epidemic phase of an emerging infectious disease, we found that COVID-19 has several other effects besides its incidence. The postponing treatment was the most common, therefore, treatment of ovarian tumors and ovarian cancer was considered to be the most likely to be affected among gynecological diseases. Protocols that allow for easy over-diagnosis can be disadvantageous, mainly because of treatment delays, and therefore, the protocols must be developed in light of the local infection situation.

show abstract

Section: Susceptibility Of the Treatment Strategies For Ovarian Tumormentioning

confidence: 99%

Section: Susceptibility Of the Treatment Strategies For Ovarian Tumormentioning

confidence: 99%

Impact of the COVID-19 epidemic at a high-volume facility in gynecological oncology in Tokyo, Japan: a single-center experience

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Some gynecologic cancer societies have shared their strategies to treat gynecologic cancer patients during this time, providing options to decrease the risk of transmission and simultaneously reducing the pressure on health systems. [1][2][3][4] As efforts to contain the spread of COVID-19 are starting to show declines in the number of positive cases in many regions, it is time to question how healthcare systems are going to address the post-pandemic care of patients with gynecologic cancers. One of the most important challenges is how to restart routine clinical activity where the infection risk is still present and restrictions on hospital visits are necessary.…”

Section: Introductionmentioning

confidence: 99%

Gynecologic cancer surveillance in the era of SARS-CoV-2 (COVID-19)

Mancebo

Solé-Sedeño

Membrive

et al. 2020

Int J Gynecol Cancer

View full text Add to dashboard Cite

The SARS-CoV-2 (COVID-19) pandemic has significantly impacted the management of patients with gynecologic cancers. Many centers have reduced access to routine visits to avoid crowded waiting areas and specially to reduce the infection risk for oncologic patients. The goal of this review is to propose a surveillance algorithm for patients with gynecologic cancers during the COVID-19 pandemic based on existing evidence and established guidelines. It is time to consider strategies based on telemedicine and to adapt protocols in this new era. We hereby propose a strategy for routine surveillance both during and beyond the pandemic.

show abstract

“…There have also been several preliminary international guidelines published on the management of cancer patients in the setting of COVID-19 ( Table 1 ) [ 15 , 19 , 20 , 21 ]. Additional guidelines published for specific countries and published in other languages, as well as specific disease states, have previously been summarized [ 22 , 23 , 24 , 25 ]. However, these triaged guidelines are mostly non-specific and may have contributed to significant inconsistency between providers and centers.…”

Section: Discussionmentioning

confidence: 99%

Cancer in the Time of Coronavirus: A Call for Crisis Oncology Standards of Care

Kelkar

Cogle

2020

Healthcare

View full text Add to dashboard Cite

Since the Coronavirus Disease 2019 (COVID-19) was identified as a global pandemic, health systems have been severely strained, particularly affecting vulnerable populations such as patients with cancer. In response to the COVID-19 pandemic, a variety of oncology specialty societies are making recommendations for standards of care. These diverse standards and gaps in standards can lead to inconsistent and heterogeneous care among governments, cancer centers, and even among oncologists within the same practice. These challenges highlight the need for a common nomenclature and crisis guidelines. For times of increased scarcity of resources, the National Academy of Medicine developed Crisis Standards of Care, defined as fairness, duty to care, duty to steward resources, transparency, consistency, proportionality, and accountability. However, we believe there is an urgent need to develop cancer-specific guidelines by convening a panel of experts from multiple specialties. These would be Crisis Oncology Standards of Care (COSCs) that are sensitive to both the individual cancer patient and to the broader health system in times of scarce resources, such as pandemic, natural disaster, or supply chain disruptions.

show abstract

COVID-19 and gynecological cancer: a review of the published guidelines

Cited by 47 publications

References 30 publications

Impact of the COVID-19 epidemic at a high-volume facility in gynecological oncology in Tokyo, Japan: a single-center experience

Impact of the COVID-19 epidemic at a high-volume facility in gynecological oncology in Tokyo, Japan: a single-center experience

Gynecologic cancer surveillance in the era of SARS-CoV-2 (COVID-19)

Cancer in the Time of Coronavirus: A Call for Crisis Oncology Standards of Care

Contact Info

Product

Resources

About